Nastech Pharm announces initiation of Phase 2 clinical trial for PYY3-36 nasal spray to treat obesity

Co announces the start of a Phase 2 clinical trial evaluating the co's PYY3-36 Nasal Spray in obese patients. The study will enroll approximately 500 obese patients for a six-month, randomized, placebo-controlled dose ranging study with weight loss as the primary endpoint.